Barclays analyst Matt Miksic raised the firm’s price target on Orchestra BioMed (OBIO) to $12 from $11 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO: